Nebivolol Starting Dose for ACS NSTEMI
Nebivolol is not specifically recommended for NSTEMI, and you should use a different beta blocker with established evidence in acute coronary syndromes. The major guidelines for NSTEMI management do not mention nebivolol, and the FDA labeling explicitly states that nebivolol has not been studied in patients with angina pectoris or recent MI 1.
Why Not Nebivolol?
The evidence base for beta blockers in NSTEMI comes from trials using metoprolol, carvedilol, atenolol, and propranolol—not nebivolol. The 2014 AHA/ACC NSTEMI guidelines 2 and the 2025 ACC/AHA ACS guidelines 3 recommend oral beta-blocker therapy within the first 24 hours but do not specify nebivolol as an appropriate agent for this indication.
Critical FDA Warning: Nebivolol's drug label specifically states it "was not studied in patients with angina pectoris or who had a recent MI" 1. This is a major red flag for use in NSTEMI.
What Beta Blocker Should You Use Instead?
Start metoprolol tartrate 25-50 mg orally twice daily (or carvedilol 3.125-6.25 mg twice daily) within the first 24 hours, provided the patient does not have 4, 2, 5:
- Signs of heart failure (Killip class II-IV)
- Evidence of low-output state
- Increased risk for cardiogenic shock (age >70, SBP <120 mmHg, HR >110 or <60, prolonged symptom duration)
- PR interval >0.24 seconds
- Second- or third-degree heart block without pacemaker
- Active asthma or reactive airway disease
Avoid intravenous beta blockers in NSTEMI—they increase cardiogenic shock risk without clear benefit 2, 3.
If You Absolutely Must Use Nebivolol (Not Recommended)
If there is a compelling reason to use nebivolol specifically (e.g., patient already tolerating it for hypertension), the FDA-approved starting dose is 5 mg once daily for hypertension 1. However, in the acute MI setting:
- Consider starting at 2.5 mg once daily (the dose used for renal/hepatic impairment) and titrate slowly
- One observational study used 1.25 mg daily in post-MI patients, though this showed higher MI recurrence rates compared to standard doses 6
- The FDA label allows titration up to 40 mg daily for hypertension, but this has no evidence base in ACS
Common Pitfalls to Avoid
- Do not give IV beta blockers acutely in NSTEMI—this increases cardiogenic shock risk 2
- Do not use nebivolol as first-line—it lacks evidence in ACS and has explicit FDA warnings against use in recent MI 1
- Do not abruptly discontinue beta blockers if already on them—taper over 1-2 weeks to avoid rebound ischemia 1
- Reassess contraindications after 24 hours—patients initially unsuitable may become candidates once stabilized 3
Bottom Line
Use metoprolol or carvedilol, not nebivolol, for NSTEMI. Start low-dose oral therapy within 24 hours if no contraindications exist, and titrate up as tolerated during hospitalization and after discharge.